Johnson & Johnson Close to Settling Off-Label Probes
Published: Jun 21, 2012
Johnson & Johnson is close to reaching a settlement with the U.S. Justice Department over allegations it promoted anti psychotic drug Risperdal for unapproved uses that could cost the healthcare conglomerate at least $1.5 billion, the Wall Street Journal reported on Wednesday. The report, citing anonymous sources familiar with the matter, said the sides are discussing a deal of between $1.5 billion and $1.7 billion that could be finalized in a few weeks. It also said the final amount could exceed $2 billion.